Beyond Herceptin: Kadcyla Carries Torch Across Lines Of HER2 Therapy

Genentech’s HER2 program director Dietmar Berger shares broader plans for Kadcyla (ado-trastuzumab emtansine) following its approval in second-line mBC, and expects Herceptin will continue to play a role in the long term.